Search Results - therapeutics+%3e+hematology

18 Results

Sort By:

Novel Lipid Lowering, Anti-Atherosclerosis and Anti-Obesity Effects of Netrin-1 (UCLA Case No. 2019-728)

UCLA researchers in the Department of Anesthesiology have developed a novel and extremely robust lipid lowering, anti-atherosclerotic, and anti-obesity treatment with Netrin-1.BACKGROUND:Hyperlipidemia, an elevation of different forms of lipids in the bloodstream, is the most important risk factor for coronary heart disease, while causing many other...

Published: 3/26/2026 | Inventor(s): Hua Cai

Keywords(s): Cardiovascular, Hematology, Therapeutics & Vaccines

Category(s): Therapeutics > Cardiovascular, Therapeutics > Hematology

Engineered Gamma Delta T-Cells and Methods of Making and Using Thereof (UCLA Case No. 2020-913)

UCLA researchers in the Department of Molecular Immunology & Molecular Genetics have developed gamma delta (gd) T cell receptor gene-modified immune cells derived from stem and progenitor cells that enable scalable, off-the-shelf allogeneic cell therapies with broad therapeutic potential. BACKGROUND: Cell-based immunotherapies have demonstrated...

Published: 3/4/2026 | Inventor(s): Lili Yang, Derek Lee, Tyler Halladay

Keywords(s):

Category(s): Diagnostic Markers > Immunology, Diagnostic Markers > Cancer, Life Science Research Tools > Cell Lines, Therapeutics > Oncology, Therapeutics > CNS and Neurology, Therapeutics > Hematology, Therapeutics > Autoimmune, Therapeutics > Gene Therapy And Editing, Therapeutics > Stem Cells And Regenerative Medicine, Therapeutics > Infectious Diseases

TYRP-1 Chimeric Antigen Receptor to Treat Melanoma (UCLA Case No. 2020-106)

UCLA researchers in the Departments of Surgical Oncology and Microbiology, Immunology, & Molecular Genetics. have developed a CAR-T therapy that targets TYRP-1 for the treatment of melanoma. BACKGROUND: Immune checkpoint blockade (ICB) is a rapidly emerging immunotherapy approach that uses patients’ immune cells to treat cancer. In contrast...

Published: 4/20/2026 | Inventor(s): Cristina Puig Saus, Antoni Ribas, Yvonne Chen

Keywords(s): Gene Therapy, Hematology, Immunotherapy, Research Methods

Category(s): Therapeutics > Hematology

Vectors Combining Anti-Sickling Beta-AS3-Globin with Anti BCL11A ShRNAmir to Treat Beta-Hemoglobinopathies (UCLA Case No. 2021-190)

UCLA researchers from the Department of Microbiology, Immunology and Molecular Genetics and Pediatrics have developed a potent bi-functional lentiviral expression vector to treat sickle cell disease and beta-thalassemia. BACKGROUND: Beta-hemoglobinopathies, such as sickle cell disease and beta-thalassemia, are genetic disorders characterized by dysfunctional...

Published: 9/11/2025 | Inventor(s): Donald Kohn

Keywords(s):

Category(s): Therapeutics > Gene Therapy And Editing, Therapeutics > Hematology, Therapeutics > Stem Cells And Regenerative Medicine

Hemodynamics Driven Magnetoelastic Vascular Graft (Case No. 2025-124)

Summary: UCLA researchers in the Department of Bioengineering have developed a novel magnetoelastic vascular graft to provide real-time, wireless, and continuous stenosis monitoring. TITLE: Hemodynamics Driven Magnetoelastic Vascular Graft Background: Vascular grafts are commonly used to restore blood flow in patients with blocked or damaged blood...

Published: 5/28/2026 | Inventor(s): Jun Chen, Song Li, Guorui Chen

Keywords(s): cardiovascular monitoring, Diagnostic Platform Technologies (E.G. Microfluidics), hemodynamic monitoring, Hemodynamics, magnetoelastic sensor, Medical diagnostics, Vascular therapy

Category(s): Diagnostic Markers > Immunology, Life Science Research Tools > Screening Libraries, Medical Devices > Monitoring And Recording Systems, Therapeutics > Autoimmune, Therapeutics > Immunology And Immunotherapy, Therapeutics > Transplant, Therapeutics > Hematology, Therapeutics > Cardiovascular

Single-Chain Bispecific Chimeric Antigen Receptor Targeting BCMA and CS1 for the Treatment of Multiple Myeloma (UCLA Case No. 2018-680)

UCLA researchers in the Department of Chemical and Biomolecular Engineering have developed a single-chain bispecific chimeric antigen receptor targeting BCMA and CS1 for treating multiple myeloma. BACKGROUND: Multiple myeloma (MM) is a cancer of the plasma cells that accounts for over 30,000 new diagnoses each year, according to the American Cancer...

Published: 7/31/2025 | Inventor(s): Yvonne Chen, Eugenia Zah

Keywords(s): Hematology, Immunotherapy, Life Science Research Tools, Therapeutics & Vaccines

Category(s): Life Science Research Tools, Therapeutics > Immunology And Immunotherapy, Therapeutics > Hematology

Identification of a Factor That Rescues Dysregulated Endocytosis in Cultured Human Hematopoietic Stem Cells (UCLA Case No. 2023-051)

UCLA researchers in the Departments of Molecular, Cell & Developmental Biology have developed a novel method to enhance the function of hematopoietic stem cells (HSCs) to improve the transplantability of ex vivo expanded human HSCs in clinical settings. BACKGROUND: Hematopoietic stem cells (HSCs), present in blood and bone marrow, can form mature...

Published: 12/2/2025 | Inventor(s): Hanna Mikkola, Julia Aguade Gorgorio

Keywords(s): bone marrow, bone marrow transplants, CRISPR, endocytosis, engraftment, environmental sensing, hematopoietic stem cells, leukemia, MLLT3, MYCT1, transplantability

Category(s): Therapeutics > Hematology, Life Science Research Tools, Therapeutics > Stem Cells And Regenerative Medicine

Alleviating GvHD Using Engineered INKT Cells (UCLA Case No. 2023-019)

SUMMARY: Researchers in UCLA’s Department of Microbiology, Immunology & Molecular Genetics have developed an off-the-shelf cell therapy method for reduction of Graft vs Host Disease (GvHD) following hematopoietic stem cell transplantation. This approach uses engineered third-party iNKT’s to ameliorate severity of GvHD without negatively...

Published: 7/31/2025 | Inventor(s): Lili Yang

Keywords(s): Hematology, Stem-Cell Therapy, T Cell, Therapeutics & Vaccines

Category(s): Therapeutics, Therapeutics > Hematology

2021-189: NOVEL AND ROBUST COMBINATORY THERAPY FOR AORTIC ANEURYSMS

SUMMARY: Researchers from UCLA’s Department of Anesthesiology have developed an oral combinatory therapy that holds enormous implications in healthcare for the complete attenuation of aneurysm formation. BACKGROUND: Aortic aneurysms are abnormal protrusions in the major blood vessels from the heart to the rest of the body. These protrusions...

Published: 7/17/2025 | Inventor(s): Hua Cai

Keywords(s):

Category(s): Therapeutics > Cardiovascular, Therapeutics > Hematology

Novel IGE Antibodies for the Therapy of Cancer (UCLA Case No. 2021-043)

Researchers at UCLA’s David Geffen School of Medicine have designed three novel antibodies of the IgE class targeting antigens CD138, CD38, and transferrin receptor 1 (TfR1/CD71): cancer antigens present in various hematopoietic and/or solid tumors. There are several advantages of IgE class antibodies compared to the commonly used IgG class in...

Published: 6/1/2026 | Inventor(s): Manuel Penichet, Pierre Candelaria, Miguel Nava, Tracy Daniels-Wells

Keywords(s): Cancer, Immunoglobulin G

Category(s): Platforms > Drug Delivery > Peptide Base, Therapeutics > Hematology

1 2